This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol. 1997;15:451–7.
Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double blind, randomized trial. Bone Marrow Transplant. 2004;34:955–62.
Trifilio S, Zhou Z, Galvin J, Fong JL, Monreal J, Mehta J. Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question. Clin Transplant 2015;29(Dec):1128–32.
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199–212.
Metcalf D. Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science 1991;254:529–33.
Demirer T, Ayli M, Dagli M, Haznedar R, Genc Y, Fen T, et al. Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol. 2002;118:1104–11.
Piccirillo N, Sica S, Laurenti L, Chiusolo P, La Barbera EO, Sora F, et al. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 1999;23:1245–50.
de Azevedo AM, Nucci M, Maiolino A, Vigorito AC, Simoes BP, Aranha FJ, et al. A randomized, multicenter study of GCSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 2002;29:745–51.
Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H, et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant. 1998;22:965–9.
Cottini F, Sborov D, Yu KC, Lamprecht M, Tackett K, Li J, Devine SM, Poi M, Phelps MA, Hofmeister CC. G-CSF starting day +1 after autologous transplant is safer than day +5 or day +7 in patients with multiple myeloma. Blood 2016;128:5790.
Faber E, Pytlik R, Slaby J, Zapletalova J, Kozak T, Raida L, et al. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma—results of a prospective multicentre controlled trial. Eur J Haematol. 2006;77:493–500.
Singh AD, Parmar S, Patel K, et al. Granulocyte colony-stimulating factor use after autologous peripheral blood stem cell transplantation: comparison of two practices. Biol Blood Marrow Transplant. 2018;24:288–93.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ali, N., Cooper, B., Tomlinson, B. et al. Treatment-related mortality following autologous hematopoietic stem cell transplantation is unaffected by timing of G-CSF administration. Bone Marrow Transplant 55, 1697–1700 (2020). https://doi.org/10.1038/s41409-020-0812-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-0812-x